Clinical trials: Blood Clots
Intracranial Embolism, Thrombosis
Ultrasound Enhanced Thrombolytic Therapy of Middle Cerebral Artery Occlusion
The purpose of the present, randomized, controlled multicenter phase III trial is to investigate the safety and efficacy of continuous 1-hour insonation of occluded middle cerebral artery with 2 MHz TCCS in stroke patients…
- Trial name
- NCT00336596
- Testing
- transcranial ultrasound in patients treated with iv t-PA
- Where
- 6 sites in Switzerland
- Volunteers
- 400 people
- Sponsor
- University of Zurich
CHAPLE Disease
A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) Disease
This study is researching a drug called pozelimab (called "study drug"). The main aim of this study is to monitor the safety and tolerability of the study drug.
- Trial name
- NCT07142343
- Testing
- Pozelimab
- Where
- Turkey (Türkiye)
- Volunteers
- 5 people
- Sponsor
- Regeneron Pharmaceuticals
Catheter Related Complication
Duplex Ultrasonography Performed by Nurses
Catheter-related thrombosis (CRT) has been found as the major complication of the established central venous catheter in intensive care unit (ICU) patients. Its reported incidence varies from 5 to 66 %.
- Trial name
- NCT03924583
- Testing
- Duplex ultrasonography
- Where
- Czechia
- Volunteers
- 150 people
- Sponsor
- Masaryk Hospital Krajská zdravotní a.s.
Age Related Macular Degeneration, Central Retinal Vein Occlusion
Ziv-aflibercept in Eyes With Retinal Diseases and Poor Vision-phase I
Aflibercept is FDA approved and the same molecule is available as hyperosmolar for oncology (cost 800 USD for 4ml) and isoosmolar for Ophthalmology (cost 1,770 USD for 0.05ml injection).
- Trial name
- ZIV (NCT02173873)
- Testing
- ziv-aflibercept drug
- Where
- Lebanon
- Volunteers
- 100 people
- Sponsor
- Rafic Hariri University Hospital
Magnetic Resonance Imaging, Cerebral Venous Sinus Thrombosis
Application CT and MRI in Cerebral Venous Sinus Thrombosis
Cerebral venous thrombosis (CVT) is a rare disease, and with poor prognosis. Computed tomography (CT) andmagnetic resonance imaging (MRI) are the most commonly used image modalities for patients with non-specific neurologic…
- Conditions
- Magnetic Resonance Imaging, Cerebral Venous Sinus Thrombosis, Computer Tomographgy
- Trial name
- NCT04966182
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hay Fever, Asthma
Evaluating the Potential of Large Language Models for Respiratory Disease Consultations
The clinical trial aimes to evaluate multiple large language models in respiratory disease consultations by comparing their performance to that of human doctors across three major medical consultation scenarios.
- Conditions
- Hay Fever, Asthma, Acute Upper Respiratory Infection, Pulmonary Embolism
- Trial name
- EPLLMMRDC (NCT06457269)
- Testing
- Diagnosis by three human doctors, Diagnosis by ChatGPT-3.5 (with search capabilities), Diagnosis by ChatGPT-3.5 (without search capabilities)
- Where
- China
- Volunteers
- 703 people
- Sponsor
- North Sichuan Medical College
Neovascularization, Macular Degeneration
Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection
Background/aims: Aflibercept is an approved therapy for neovascular macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion and other retinal conditions.
- Conditions
- Neovascularization, Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion
- Trial name
- Zaltrap (NCT02486484)
- Testing
- ziv-aflibercept
- Where
- Lebanon
- Volunteers
- 100 people
- Sponsor
- Rafic Hariri University Hospital
Liver Cirrhosis, Venous Thromboembolism
Risk Factors and Outcomes of Acute Venous Thromboembolism in Cirrhotic
patient with liver cirrhosis was supposed to have autoanticoagulation which approved to be wrong, with absence of conventional method to detect all abnormalities in coagulation state.
- Trial name
- NCT03580577
- Testing
- thromboelastography
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Assiut University
Cerebral Vein Thrombosis
Rivaroxaban vs. Warfarin in CVT Treatment
Cerebral venous thrombosis (CVT) is an uncommon venous-type of stroke tends to affect younger patients with somewhat different risk factors and much better outcome compared to arterial strokes.
- Trial name
- RWCVT (NCT04569279)
- Testing
- Rivaroxaban, Warfarin
- Where
- Syria
- Volunteers
- 71 people
- Sponsor
- Damascus University
Coronary Artery Disease
Assessment of Distal Protection Device in Patients at High Risk for Distal Embolism in Acute Coronary Syndrome (ACS)
Attenuated plaque ≥ 5mm by intravascular ultrasound(IVUS) was reported to be high risk for distal embolism in Acute coronary syndrome(ACS).
- Trial name
- VAMPIRE3 (NCT01460966)
- Testing
- Filtrap™ + Thrombus aspiration catheter, Thrombus aspiration catheter
- Where
- Japan
- Volunteers
- 200 people
- Sponsor
- Yokohama City University Medical Center
Venous Thromboembolism
An Observational Study to Learn More About How Safe Treatment With Rivaroxaban is in Children in Japan With Venous Thromboembolism
This is an observational study in which only data will be collected from children with venous thromboembolism who are prescribed rivaroxaban or warfarin by their doctors.
- Trial name
- NCT06278051
- Testing
- Rivaroxaban granules for oral suspension, Warfarin
- Where
- 2 sites in Japan
- Volunteers
- 320 people
- Sponsor
- Bayer
Hemophilia A, Hemophilia A, Severe
Hemophilia A Research Program
This study longitudinally observes the intergenerational (mother-child) continuum in hemophilia A from pregnancy through early childhood.
- Conditions
- Hemophilia A, Hemophilia A, Severe, Factor VIII (FVIII), FVIII Deficiency
- Trial name
- HARP (NCT07414511)
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- University of Washington
Preterm Birth, Coagulation Protein Disorders
Stratifying Risk for Intracerebral Haemorrhage
This study aims to investigates the role of gestational age on the prevalence of coagulation factors and components of the complement system in preterm- (≤32+0 weeks) and term neonates (≥37+0 weeks) and their role for the…
- Conditions
- Preterm Birth, Coagulation Protein Disorders, Coagulation Disorder Neonatal
- Trial name
- NEW_STRATEGI (NCT04140812)
- Testing
- mass spectrometry (LC-MS/MS)
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Erlangen-Nürnberg Medical School
Brain Tumor, Vascular Lesion
Factor XIII and Pulmonary Embolism in Neurosurgical Patients
Two studies (Gerlach et al. 2000; Gerlach et al. 2002) described the impact of factor XIII on the risk of prospective hemorrhage for patients undergoing craniotomy.
- Conditions
- Brain Tumor, Vascular Lesion, Factor XIII Deficiency, Pulmonary Embolism
- Trial name
- NCT01106937
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Venous Thromboembolism
Pilot Feasibility and Safety of Administering Weight Adjusted Fixed LMWH Dose
Background Enoxaparin is a commonly used low molecular weight heparin (LMWH) for the treatment of neonatal and children thrombosis that is monitored with anti-factor Xa (anti-Xa) levels.
- Trial name
- FiXET (NCT02486666)
- Testing
- Enoxaparin
- Where
- 4 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- Hamilton Health Sciences Corporation
Portal Vein Thrombosis
Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis
-Rivaroxaban is factor Xa inhibitor
- Trial name
- NCT03193502
- Testing
- rivaroxaban
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Sherief Abd-Elsalam
Thrombosis
Risk Factors of Neonatal Thrombosis
The incidence of symptomatic thrombosis is between 2.4 and 6.8 per 1000 neonatal intensive care unit admission while it is 5.1 per 100 000 live births.
- Trial name
- NCT05367466
- Volunteers
- 11 people
- Sponsor
- Kırıkkale University
Venous Thromboembolism
Effect of the Genotype on Postoperative DVT
Postoperative Venous Thromboembolism Events (VTE) constitute a major source of morbidity and mortality after surgery. The aim of this study was to investigate whether commonly occurring Single Nucleotide Polymorphisms (SNPs) are…
- Trial name
- NCT04940377
- Where
- Denmark
- Volunteers
- 502,505 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Cardiac Disease
Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease
A committee will judge the safety and effectiveness of edoxaban and the regular treatment (standard of care). All children in the study will receive free treatment.
- Trial name
- NCT03395639
- Testing
- Edoxaban, Standard of Care (SOC)
- Where
- 48 sites in United States, Austria and 12 more
- Volunteers
- 168 people
- Sponsor
- Daiichi Sankyo
Thrombosis Portal Vein
TIPS or Anticoagulation in Portal Vein Thrombosis
The PROGRESS is an investigator-initiated, multicentre, randomized, trial comparing anticoagulation, which is the currently most frequently used treatment, alone, versus transjugular intrahepatic portosystemic shunt (TIPS)…
- Trial name
- PROGRESS (NCT03422419)
- Testing
- Heparin, TIPS
- Sponsor
- Insel Gruppe AG, University Hospital Bern